Align Technology ALGN
United StatesHealthcare · Medical Instruments & SuppliesUSD
201.71 USD (+44.2%)
14 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Align Technology is a medical technology company that designs and manufactures the Invisalign clear aligner system and iTero intraoral scanners, selling its products to orthodontists and dentists worldwide.
Key points
from its scores- ✓Very solid balance sheet7.8
- ✓Good share-price trend7.3
- ✓High-quality business7.2
- ✕Little or no dividend1.5
- ✕Unfavourable risk and backdrop3.2
AI analysis
bottom line, main risk, context and newsValuation is reasonable and the balance sheet is solid, but the lack of growth and absence of clear catalysts limit the upside potential in the short term.
Align Technology shows solid financial health with net cash (ND/EBITDA of -1.06) and an attractive valuation (forward P/E of 11.21, PEG of 0.60), although its growth has stalled with revenue growth of only 4.30% and a -12.10% decline in earnings.
The main risk is the slowdown in revenue growth (4.30%) and the decline in earnings (-12.10%), which could indicate a saturation of the clear aligner market or increased competition.
Context and risks
Align Technology has no recent relevant news. Its clear aligner and intraoral scanner business has no material exposure to interest rates, oil prices, or shipping routes. The current macro context does not directly and demonstrably affect its fundamentals.
Is Align Technology stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 21% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 24.3 | 26.7 | −9% |
| EV / EBITDA | 9.7 | 14.5 | −33% |
| Price / book | 2.4 | 4.1 | −43% |
| Price / sales | 2.4 | 3.4 | −30% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 7.1 out of 10 (median for Healthcare: 4.7).
Average analyst target: 201.71 USD, +44.2% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 7.8 (sector 6.5), Growth 3.9 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 24.3
- Forward P/E
- 11.2
- EV / EBITDA
- 9.7
- Price / book
- 2.4
- Price / sales
- 2.4
- PEG
- 0.60
- Market cap
- 9.9B USD
- Enterprise value
- 9.0B USD
Profitability
- ROE
- 10.2%
- ROA
- 7.6%
- ROIC (approx.)
- 17.4%
- Gross margin
- 70.7%
- Operating margin
- 18.2%
- Net margin
- 10.0%
- Free cash flow
- 594.1M USD
- FCF yield
- 6.0%
- Cash conversion
- 64%
Solvency
- Total debt
- 120.8M USD
- Net debt
- −981.7M USD
- Cash
- 1.1B USD
- EBITDA
- 925.7M USD
- Net debt / EBITDA
- −1.06
- Debt / equity
- 2.85
- Current ratio
- 1.40
- Quick ratio
- 1.20
Growth
- Revenue growth
- +4.3%
- Earnings growth
- −12.1%
- EPS (TTM)
- 5.75 USD
- EPS (forward)
- 12.48 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.67
- Analyst consensus
- Buy (14)
- Target price
- 201.71 USD
- 52-week range
- 124.91 – 200.44
Recent news
All ALGN news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Align Technology
Is Align Technology stock cheap or expensive?
On P/E and EV / EBITDA, it trades 21% below the Healthcare median on average. Valuation score: 7.1 out of 10 (median for Healthcare: 4.7). Average analyst target: 201.71 USD, +44.2% versus the price. This is not investment advice.
What score does Align Technology get on MeridIAn Screener?
It scores 5.8 out of 10, rank 1,127 of 2,130 (better than 43% of the companies analysed). Its strongest category is Financial health (7.8) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Align Technology's P/E ratio?
Its P/E is 24.3: the share price equals 24.3 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 11.2.
How much is Align Technology worth on the stock market?
Its market capitalisation is 9.9B USD and its enterprise value, debt included, is 9.0B USD.
How much debt does Align Technology have?
It has more cash than debt: net cash of 981.7M USD.
Does Align Technology pay a dividend?
It pays no dividend, or almost none.
How has Align Technology stock performed over the last year?
It has risen 11.2% over the last year, excluding dividends. Over the last 52 weeks it has traded between 124.91 and 200.44 USD. Past performance does not guarantee future results.
What do analysts think of Align Technology?
14 analysts cover it; their average recommendation is “Buy” and their average target is 201.71 USD (+44.2% versus the price). It is an estimate, not market data.